Two venture capital firms Foresite Capital and F-Prime Capital completed a $30m funding round in Genomics, a biotech company. Additional investors include Oxford Sciences Innovation and Lansdowne Partners. “We are delighted to be supported by leading life sciences investors who share our vision. We have known for over 50 years that genetics plays a key role in risk for all the common chronic diseases and cancers, and now we have a robust way to calculate that risk,” Sir Peter Donnelly, Genomics Co-Founder and CEO.